MYD88 and CD79B showed high mutation frequencies in the cohort, 64% and 48%, respectively, significantly higher than those in systemic DLBCL (15)), followed by TP53 (19.8%), TET2 (12.5%), KMT2D (12.5%), PIM1 (8.3%), PTEN (7.8%), APC (7.3%), RB1 (6.7%), and KIT (5.2%) (Fig. 1A). This evidence concerns the gene PIM1 and diffuse large B-cell lymphoma.